The pharmaceuticals major was boosted by high demand for its key drugs that offset a slight sales drop in China.

Pharma giant AstraZeneca urged Britain to improve the environment for businesses in order to drive investment, days after it ...

London's blue-chip index jumped to a record high on Thursday, lifted by shares of AstraZeneca after upbeat results and ahead ...

AstraZeneca has ended development of its oral factor D inhibitor vemircopan, triggering a $753 million impairment charge as ...

The company said, “In relation to the illegal drug importation allegations, in January 2025, AstraZeneca (AZN) received a Notice of Transfer to ...

Reports Q4 reported EPS 97c vs. 62c last year. Reports Q4 revenue $14.89B, consensus $14.28B. Pascal Soriot, CEO, AstraZeneca (AZN), ...

Harvey Jones hails the brilliant long-term performance of the AstraZeneca share price, but wonders whether the FTSE 100's ...

AstraZeneca said the taxes related to two cancer drugs, Imfinzi and Imjudo, and that it was continuing to co-operate with ...

Sales in China fell 3 per cent during the quarter. AstraZeneca said this was mainly because the winter had been mild, causing a drop in sales of respiratory drugs used to treat viral infections. It ...

AstraZeneca has cancelled a multi-million pound investment in a vaccine plant in Merseyside because the government failed to ...

AstraZeneca Plc reported better-than-expected profit and sales in the fourth quarter and forecast further gains as the UK drugmaker’s blockbuster cancer drugs offset weakened China sales.

Strong momentum in FY 2024 with Total Revenue and Core EPS up 21% and 19% respectively AstraZeneca: Revenue and EPS summary FY 2024 % Change Q4 2024 ...